Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine

被引:27
作者
Bot, AI
Smith, DJ
Bot, S
Dellamary, L
Tarara, TE
Harders, S
Phillips, W
Weers, JG
Woods, CM
机构
[1] Alliance Pharmaceut Corp, Dept Biol Res, San Diego, CA 92121 USA
[2] Alliance Pharmaceut Corp, Dept Pharmaceut Res, San Diego, CA 92121 USA
关键词
microparticles; ligand; cell targeting; vaccines; surfactant-lipid;
D O I
10.1023/A:1010988311640
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Spray-dried lipid-based microparticles (SDLM) serve as a platform for delivery of a wide variety of compounds including peptides, proteins, and vaccines to the respiratory mucosa. In the present study, we assessed the impact of IgC-mediated targeting to phagocytic cells of inactivated influenza virus formulated in SDLM, on subsequent immune responses. Methods. SDLM were produced containing inactivated influenza virus strain A/WSN/32/H1N1 (WSN), with or without IgG. Using phagocytic antigen presenting cells (APC) and a T cell hybridoma (TcH) line specific for a dominant influenza virus epitope, we compared the in vitro responses elicited by ligand-formulated (SDLM-IgG-WSN) and non-ligand particles (SDLM-WSN). The effect of including the IgG ligand in the formulation was further characterized by measuring the immune responses of rodents vaccinated with SDLM. Results. SDLM-IgG-WSN were internalized in an Pc receptor (FcR)-dependent manner by phagocytic APC that were then able to effectively present a dominant, class II-restricted epitope to specific T cells. While SDLM-WSN elicited a lower response than administration of plain inactivated virus in saline, the level of the T cell response was restored both in vitro and in vivo by incorporating the APC FcR ligand, IgG, in the SDLM. Conclusions. Incorporation of FcR ligand (IgG) in SDLM restored the limited ability of formulated virus to elicit T-cell immunity, by receptor-mediated targeting to phagocytes.
引用
收藏
页码:971 / 979
页数:9
相关论文
共 32 条
[1]  
Allison A C, 1976, Recent Results Cancer Res, P58
[2]  
Allison AC, 1998, DEV BIOL STAND, V92, P3
[3]   SEDIMENTATION OF INFLUENZA VIRUS AND ITS RNA IN SUCROSE DENSITY GRADIENTS [J].
BARRY, RD ;
DAVIES, P .
JOURNAL OF GENERAL VIROLOGY, 1968, 2 :59-&
[4]   Comparison of neutralizing and hemagglutination-inhibiting antibody responses to influenza A virus vaccination of human immunodeficiency virus-infected individuals [J].
Benne, CA ;
Kroon, FP ;
Harmsen, M ;
Tavares, L ;
Kraaijeveld, CA ;
De Jong, JC .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1998, 5 (01) :114-117
[5]  
Bot A, 1996, J IMMUNOL, V157, P3436
[6]   Cellular mechanisms involved in protection and recovery from influenza virus infection in immunodeficient mice [J].
Bot, A ;
Reichlin, A ;
Isobe, H ;
Bot, S ;
Schulman, J ;
Yokoyama, WM ;
Bona, CA .
JOURNAL OF VIROLOGY, 1996, 70 (08) :5668-5672
[7]   Protective role of gamma interferon during the recall response to influenza virus [J].
Bot, A ;
Bot, S ;
Bona, CA .
JOURNAL OF VIROLOGY, 1998, 72 (08) :6637-6645
[8]  
Bot A., 1999, Recent Research Developments in Virology, V1, P317
[9]   Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract [J].
Bot, AI ;
Tarara, TE ;
Smith, DJ ;
Bot, SR ;
Woods, CM ;
Weers, JG .
PHARMACEUTICAL RESEARCH, 2000, 17 (03) :275-283
[10]  
CASTRO A, 1997, EUR J CELL BIOL, V4, P321